both ES2 and Skov3 monolayer viability, while spheroid viability
was minimally impacted only at the highest concentrations.
Combining either cisplatin or taxol with SMIFH2 did not significantly
enhance the effects of either drug alone in ES2 monolayers,
while Skov3 monolayers treated with taxol or cisplatin with
SMIFH2 showed significant additive effects upon inhibition of
viability. Interestingly, when we treated EOC spheroids with combined
therapy, ES2 spheroids were highly responsive to dual taxol
or cisplatin with SMIFH2 treatments, with clear additive effects
observed upon viability. In contrast, combined taxol with SMIFH2
treatment of Skov3 spheroids also showed additive effects relative
to single treatments, yet Skov3 spheroids showed no additive effects
from combined cisplatin and SMIFH2 treatments.